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The entry of human immunodeﬁciency virus type 1 (HIV-1) into
cells is mediated by a viral envelope glycoprotein (Env) complex,
consisting of a trimer of two non-covalently associated subunits, the
gp120 surface glycoprotein and the gp41 transmembrane glycopro-
tein (Wyatt and Sodroski, 1998). After the binding of gp120 to the CD4
molecule and subsequently to a chemokine receptor, CCR5 or CXCR4,
on the cell surface, the gp41 trimer forms an extended conformation
of the three helices that allows a hydrophobic fusion peptide to be
inserted into the target cell membrane, generating a pre-hairpin
intermediate that is anchored to both cellular and viral membranes.
After this step, gp41 is believed to start refolding to a more stable 6-helix bundle composed of the α-helical trimer of the N-terminal
heptad repeat (N-HR) folded into an anti-parallel conformation with
the three C-terminal heptad repeats (C-HR). This refolding brings the
viral and cellular membranes into close proximity, leading to the
formation of a fusion pore and resulting in the completion of the
fusion process (Chan and Kim, 1998; Weiss, 2003).
The C-HR-derived 36-mer peptide, T-20 (DP-178, enfuvirtide)
(Wild et al., 1993, 1994) and the 34-mer peptide, C34 (Chan et al.,
1998; Malashkevich et al., 1998), suppress HIV-1 replication by
inhibiting the process of membrane fusion. T-20 inhibits the
formation of the 6-helix bundle as well as of the fusion pore, while
C34 inhibits the formation of the 6-helix bundle (Kliger et al., 2001).
T-20 is approved for clinical use as a HIV-1 fusion inhibitor, and is able
to suppress the replication of HIV-1 variants with multi-drug
resistance to reverse transcriptase and protease inhibitors (Kilby et
al., 1998; Lalezari et al., 2003; Lazzarin et al., 2003); however, long-
term therapy with T-20 resulted in the emergence of T-20-resistant
HIV-1 variants (Greenberg and Cammack, 2004; Wei et al., 2002). C34
has not been approved for clinical use, but has the potential to be a
novel HIV-1 fusion inhibitor. In order to improve the inhibitory effect
of C34 on HIV-1 replication, we designed new C34-derived peptides
by computational analysis.
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(Gaschen et al., 2002), and is divided into four groups, M, N, O and
P. The viruses in group M are further classiﬁed into many subtypes
and circulating recombinant forms (CRFs). Among them, subtypes A,
B, C and D, as well as CRF01_AE and CRF02_AG, are themajor subtypes
and CRFs, which are responsible for the worldwide HIV-1 pandemic
(Hemelaar et al., 2006; McCutchan, 2006). Env is the most variable
HIV-1 protein with typical intersubtype and intrasubtype differences
reaching 35% and 20%, respectively (Gaschen et al., 2002). In this
report, we tested the inhibitory effect of newly designed C34-derived
peptides for in vitro replication of the following viruses: CRF01_AE
viruses, which are prevalent in southeast Asian countries, including
Thailand; subtype B viruses, which are prevalent in the Americas,
Northern Europe and Australia, and are the most extensively studied
viral population; and subtype C viruses, which are prevalent in Africa
and India, and are the most prevalent viral population in the world; as
well as a T-20-resistant variant of the subtype B reference strain,
pNL4-3 (Adachi et al., 1986).Fig. 1. Three newly designed C34-derived peptides inhibit the replication of AE-Env-, B-
Env- and C-Env-recombinant viruses more efﬁciently than the original C34. The
inhibitory effect of the indicated peptides on the replication of six AE-Env- (A), six B-
Env- (B) and six C-Env-recombinant viruses (C) was evaluated, and the IC50 values of
the peptides for inhibiting viral replication were calculated, as described in Materials
and methods. Data are presented as the means and standard errors (error bars) of three
independent experiments.Results and discussion
Screening of newly designed C34-derived peptides
We designed ten C34-derived peptides, which were expected to
interact with N-HR more strongly than the original C34 peptide
(Table 1), based on the results of molecular dynamics analysis of the
stable conformation of the 6-helix bundle consisting of N-HR and C-
HR (Kawashita, N. et al., submitted). Namely, stronger interaction
energieswere expected for the association of N-HR and these peptides
compared to the association of N-HR and C34. First, we examined the
inhibitory effect of these peptides on the replication of CRF01_AE Env
(AE-Env)-recombinant, luciferase reporter viruses. As controls, a
fusion inhibitor, T-20, and the original C34 were used. The results of
neutralization tests showed that three newly designed peptides,
KYK01, KYK02 and KYK03, inhibited the replication of AE-Env-
recombinant viruses efﬁciently (Fig. 1A), while the seven remaining
peptides did not show a stronger inhibitory effect on viral replication
than the original C34 (data now shown). KYK01 inhibited the
replication of six AE-Env-recombinant viruses more efﬁciently than
T-20 (Fig. 1A). In addition, KYK02 and KYK03 inhibited viral
replication more efﬁciently than the original C34 (Fig. 1A).
We next examined the inhibitory effect of three newly designed
peptides on the replication of subtype B Env (B-Env)- and subtype C
Env (C-Env)-recombinant viruses. The results showed that KYK01,
KYK02 and KYK03 inhibited the replication of most B-Env-recombi-
nant viruses more efﬁciently than the original C34 (Fig. 1B). In
addition, these peptides showed a similar inhibitory effect to T-20 on
the replication of most B-Env-recombinant viruses (Fig. 1B). Further-
more, these peptides inhibited the replication of most C-Env-Table 1
Amino acid sequence of C34-derived peptides used in the ﬁrst screening test.
aAmino acid residues were numbered according to the pNL4-3 gp41 sequence.
bAmino acid sequence of C34-derived peptides used in this study was aligned with
that of C34. Dots denote amino acid identity.recombinant viruses more efﬁciently than the original C34 or T-20
(Fig. 1C). Taking these results together, three newly designed
peptides, KYK01, KYK02 and KYK03, inhibited AE-Env-, B-Env- and
C-Env-recombinant viruses more efﬁciently than the original C34
(Fig. 1). In addition, these peptides showed a similar or higher
inhibitory effect onmost of the recombinant viruses compared to T-20
(Fig. 1). The interaction energies for the association of the following
pairs of molecules, KYK01/N-HR, KYK02/N-HR, KYK03/N-HR and
C34/N-HR, were expected to be −960 kcal/mol, −1388 kcal/mol,
−913 kcal/mol and −877 kcal/mol, respectively; therefore, the
results of in vitro and in silico experiments were partially correlated.
The extent of the inhibitory effect of C34-derived peptides as well
as of T-20 varied among the recombinant viruses, suggesting that the
N-HR of the HIV-1 Env studied may show variations in the amino acid
sequence. To clarify this possibility, we compared the N-HR, as well as
C-HR, sequence of the HIV-1 Env studied. The results showed that
high levels of amino acid variations were observed in C-HR, while N-
HR sequences were relatively conserved among the HIV-1 Env studied
(Table 2). We examined the correlation between variations in the N-
HR sequences and the neutralization susceptibility of the virus to the
peptides; however, no correlation was observed.
KYK01, KYK02 and KYK03 fail to inhibit the replication of the
pNL4-3-derived, T-20-resistant virus
We next examined the inhibitory effect of newly designed C34-
derived peptides on the replication of a T-20-resistant virus. To this
end, we constructed the T-20-resistant virus, pNL-T20R, by
Table 2
N-HR and C-HR sequences of HIV-1 Env studied.
aAmino acid residues were numbered according to the pNL4-3 gp41 sequence.
bSubtype classiﬁcation of HIV-1 Env studied. AE, B and C denote CRF01_AE, subtype B, and subtype C, respectively.
cN-HR and C-HR sequences of HIV-1 Env studied were aligned with that of a subtype B reference strain, pNL4-3. Dots denote amino acid identity.
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tution from valine (V) to glutamic acid (E) at position 38 of gp41] and
N42S, whichmarkedly reduced viral susceptibility to T-20 (Greenberg
and Cammack, 2004), into pNL4-3. Neutralization tests revealed that
pNL-T20R could efﬁciently replicate in the presence of 5 μM of T-20,
original C34 or a newly designed peptide (data not shown). Namely,
KYK01, KYK02 and KYK03 did not show an inhibitory effect on the
replication of the T-20-resistant virus, although these peptides could
efﬁciently inhibit the replication of most AE-Env-, B-Env- and C-Env-
recombinant viruses tested (Fig. 1).
Design of KYK01- and KYK02-derived peptides which inhibit the
replication of the T-20-resistant virus
We next attempted to modify KYK01 and KYK02, which efﬁciently
inhibited most of the Env-recombinant viruses tested, to generate a
peptide capable of inhibiting the replication of the T-20-resistant
virus, pNL-T20R. Although KYK01 showed the strongest inhibitory
effect on all Env-recombinant viruses among the peptides tested
(Fig. 1), its solubility was quite low (data not shown). In order toimprove the solubility of KYK01, we designed two peptides, KYK01-1
and KYK01-2 (Table 3). KYK01-1 contains additional amino acid
residues in its C-terminus, while KYK01-2 contains a few hydrophilic
residues in its C- and N-terminal regions (Table 3); however, the
solubility of KYK01-1 was rather deteriorated, while KYK01-2 did not
show a strong inhibitory effect on viral replication (data not shown);
therefore, we next attempted to modify KYK02 to improve its
inhibitory effect on viral replication. To this end, we introduced a
few additional amino acid substitutions to improve hydrophobic
interaction between C34-derived peptide and N-HR, especially in the
amino acid residues whose role in inhibiting viral replication has not
been sufﬁciently studied, and generated a series of KYK02-derived
peptides (Table 3). These KYK02-derived peptides contained an
amino acid substitution, S138A, which frequently appears in the C-HR
of T-20-resistant variants (Xu et al., 2005) and was recently revealed
to improve binding stability between C34 and N-HR (Izumi et al.,
2009; Watabe et al., 2009). The results of neutralization tests showed
that ﬁve peptides, KYK02-2, KYK02-4, KYK02-6, KYK02-7 and KYK02-
9, efﬁciently inhibited the replication of pNL-T20R (Fig. 2), while four
other KYK02-derived peptides could not inhibit its replication (data
Table 3
Amino acid sequence of KYK01- or KYK02-derived peptides.
aAmino acid residues were numbered according to the pNL4-3 gp41 sequence.
bAmino acid sequence of KYK01- or KYK02-derived peptides was aligned with that
of C34. Dots denote amino acid identity.
cD-Alanine residue is shown in bold.
160 B. Soonthornsata et al. / Virology 405 (2010) 157–164not shown). We next examined the inhibitory effect of ﬁve KYK02-
derived peptides on the replication of recombinant viruses containing
AE-Env, B-Env or C-Env. The results showed that four peptides,
KYK02-2, KYK02-4, KYK02-6 and KYK02-9, but not KYK02-7, inhibited
the replication of most recombinant virusesmore efﬁciently than T-20
(Fig. 2). In particular, KYK02-2, KYK02-4 and KYK02-6 uniformly
inhibited the replication of all recombinant viruses, including pNL-
T20R (Fig. 2). Dose-dependent inhibition of pNL-T20R replication by
KYK02-2, KYK02-4 and KYK02-6, but not by T-20, is shown in Fig. 3.Inhibition of HIV-1 Env-mediated cell fusion by C34-derived peptide,
KYK02-4
We next conﬁrmed that a newly designed C34-derived peptide,
KYK02-4, inhibited viral replication by suppressing the viral fusion
process. For this purpose, a co-culture experiment was carried out
using TZM-bl reporter cells (Derdeyn et al., 2000; Platt et al., 1998;
Wei et al., 2002) and 293T cells transfected with the expression
vectors for HIV-1 Env and Tat. TZM-bl cells express CD4 and co-
receptors, CCR5 and CXCR4, on the cell surface, and also contain the
HIV-1 promoter-dependent luciferase gene; thus, luciferase activity is
expected to be enhanced if HIV-1 Env-mediated cell fusion occurs
between TZM-bl cells and 293T cells expressing HIV-1 Env and Tat.Fig. 3. KYK02-2, KYK02-4 and KYK02-6, but not T-20, inhibit the replication of pNL-
T20R in a dose-dependent manner. Neutralization susceptibility of pNL-T20R to T-20
(A), KYK02-2 (B), KYK02-4 (C) and KYK02-6 (D) was studied, and the dose–response
curves of the inhibition of viral replication by those peptides were generated using
GraphPad Prism 5 software, as described in Materials and methods.
Fig. 2. Three KYK02-derived peptides, KYK02-2, KYK02-4 and KYK02-6, efﬁciently
inhibit the replication of all recombinant viruses, including a T-20-resistant virus. The
IC50 value of the peptides for inhibiting the replication of the recombinant viruses was
calculated as described in the legend to Fig. 1. The T-20-resistant virus, pNL-T20R
(T20R), was efﬁciently replicated in the presence of 5 μM T-20; thus, the IC50 value of
T-20 for inhibiting the replication of pNL-T20R was not determined (ND). Data are
presented as the means and standard errors (error bars) of three independent
experiments.The results of a co-culture experiment showed that luciferase activity
was signiﬁcantly enhanced by co-culturing TZM-bl cells with 293T
cells transfectedwith the expression vector for AE-Env, 98CC2 or pNL-
T20R Env (T20R-Env) together with the vector for Tat (Fig. 4). In
addition, KYK02-4 almost completely prevented such enhancement of
luciferase activity (Fig. 4), indicating that cell fusion between TZM-bl
cells and 293T cells expressing HIV-1 Env and Tat was inhibited by
KYK02-4. In contrast, T-20 failed to prevent the enhancement of
luciferase activity in co-culture between TZM-bl cells and 293T cells
expressing T20R-Env, as expected (Fig. 4). These results demonstrate
that a C34-derived peptide, KYK02-4, inhibited viral replication by
suppressing HIV-1 Env-mediated membrane fusion.
KYK02-4, but not C34, interacts with N36 corresponding to N-HR of
pNL-T20R
We next compared the binding efﬁciency of C34 and KYK02-4 to
the N36 peptide corresponding to N-HR of pNL4-3 (N36-wt) and pNL-
Fig. 4. KYK02-4 efﬁciently inhibits cell fusion mediated by T20R-Env and AE-Env,
98CC2, while T-20 fails to inhibit T20R-Env-mediated cell fusion. 293T cells were
transfected with the expression vectors for HIV-1 Tat and Env. Twenty-four hours later,
the transfected 293T cells were mock-treated (No peptide) or treated with the
indicated peptide (500 nM), and were then co-cultured with TZM-bl cells for 6 h, as
described in Materials and methods. Cell fusion was evaluated by measuring luciferase
activity (RLU, relative light unit) in TZM-bl cells. Data are presented as the means and
standard errors (error bars) of four independent experiments.
161B. Soonthornsata et al. / Virology 405 (2010) 157–164T20R (N36-T20R) by in vitro reaction followed by polyacrylamide gel
electrophoresis under non-denaturing conditions (Native-PAGE), as
described previously (He et al., 2008b; Liu et al., 2003). In addition, the
heat stability of the complex was examined. The results showed that
both C34 and KYK02-4 interacted efﬁciently with N36-wt (lane 3),
and the complexes were quite heat stable, at least under our
experimental conditions (lanes 4–7) (Fig. 5). In stark contrast,
KYK02-4, but not C36, was able to interact with N36-T20R, although
the binding efﬁciency of KYK02-4 to N36-T20R was lower than that to
N36-wt (Fig. 5). These results suggest that KYK02-4, but not C34, is
able to interfere with the formation of the 6-helix bundle in infection
with not only a wild-type virus, but also a T-20 resistant virus.
Structural modeling of the interaction between C34-derived peptide and
N-HR of pNL-T20R
Although the C34-derived peptide, KYK02, contained 15 amino
acid substitutions, which were expected to improve hydrophobic
interaction between N-HR and the peptide (Kawashita, N. et al,
submitted), as compared to the original C34, it could not suppress the
replication of a T-20-resistant variant of pNL4-3, pNL-T20R (data not
shown). In contrast, KYK02-2, KYK02-4 and KYK02-6 effectively
inhibited the replication of all Env-recombinant viruses tested,
including pNL-T20R (Fig. 2). We next performed structural modeling
to study how the additionally introduced amino acid substitutions
improved the interaction of N-HR with KYK02-2, KYK02-4 and
KYK02-6. These peptides contained the amino acid substitution,
S138A, which was already reported to improve binding stabilityFig. 5. KYK02-4, but not C36, interacts with N36 corresponding to N-HR of pNL-T20R. C
corresponding to N-HR of pNL4-3 (N36-wt) (A and C) or pNL-T20R (N36-T20R) (B and D) (1
incubated at 50 °C (lane 4), 60 °C (lane 5), 70 °C (lane 6) or 80 °C (lane 7) for 15 min. Native
1 nmol of N36-wt (A and C, lane 1), N36-T20R (B and D, lane 1), C34 (A and B, lane 2) and KY
N36-wt and N36-T20R (lane 1) exhibited no band, because these peptides carry net positivbetween C34 and N-HR (Izumi et al., 2009; Watabe et al., 2009).
KYK02-2, KYK02-4 and KYK02-6, but not KYK02, inhibited the
replication of pNL-T20R (Figs. 2 and 3, and data not shown),
suggesting that S138A plays a crucial role in the inhibitory effect of
these peptides on replication of the T-20-resistant virus. In addition,
KYK02-4 and KYK02-6 contained 2 additional amino acid substitu-
tions, T128V and Q141L, as compared to KYK02-2, respectively.
KYK02-4 and KYK02-6 showed a stronger inhibitory effect than
KYK02-2 on the replication of several Env-recombinant viruses tested
(Fig. 2); thus, the amino acid substitutions, T128V and Q141L, may
play a role in improving the hydrophobic interaction between the
peptide and N-HR of pNL-T20R as well as wild-type viruses. The
results of structural modeling showed that T128V and Q141L could be
predicted to improve hydrophobic interaction between N-HR and the
peptide (Fig. 6). In addition, the amino acid substitution, L150K, which
was included in KYK02, KYK02-2, KYK02-4 and KYK02-6, was
predicted to improve the interaction between N-HR and the peptide
(Fig. 6). These results suggested that multiple amino acid substitu-
tions introduced into the peptides contributed to improve the
interaction between the peptide and N-HR, and enhanced the anti-
HIV-1 activity of these C34-derived peptides.
Recently, several newly designed peptides which mimic C-HR
were reported to efﬁciently inhibit the replication of T-20-resistant
variants derived from subtype B laboratory strains, including pNL4-3
(Dwyer et al., 2007; He et al., 2008a,b; Izumi et al., 2009; Oishi et al.,
2008). In addition, some of these peptides were able to broadly inhibit
the replication of primary HIV-1 isolates of various subtypes (He et al.,
2008a,b). Newly designed C34-derived peptides, KYK02-2, KYK02-4
and KYK02-6, had different amino acid sequences from the previously
reported peptides, but were able to inhibit the replication of a T-20-
resistant variant of pNL4-3 as well as of recombinant viruses
containing subtype B, subtype C or CRF01_AE Env more efﬁciently
than T-20 (Fig. 2); thus, we believe that our study may provide
important information to develop novel antiretroviral compounds.
Materials and methods
Peptides
We calculated the stable conformation of the 6-helix bundle,
consisting of N-HR and C-HR, by molecular dynamics analysis
(Kawashita, N. et al., submitted), and designed several C34-derived
peptides, which were expected to interact with N-HR more strongly
than the original C34 peptide (Tables 1 and 3). We found that several
hydrophobic amino acid residues of C34 play a role in interacting with
N-HR (Kawashita, N. et al., submitted); therefore, we designed new34 (A and B) or KYK02-4 (C and D) (1 nmol) was incubated with the N36 peptide
nmol) for 30 min at 37 °C (lanes 3–7). Samples were then kept on ice (lane 3) or further
-PAGE analysis was then carried out as described in Materials and methods. In addition,
K02-4 (C and D, lane 2) were subjected to Native-PAGE analysis as control experiments.
e charges and may migrate up and off the gel.
Fig. 6. Structural modeling of the interaction between newly designed peptide and N-
HR of pNL-T20R. Structural modeling of the interaction of N-HR with C34 (A), KYK02-2
(B), KYK02-4 (C) or KYK02-6 (D) was performed as described in Materials and
methods. The locations of amino acid residues, E38 and S42 in N-HR (A, B, C and D,
purple), T128, S138, Q141 and L150 in C34 (A, cyan), T128, A138, Q141 and K150 in
KYK02-2 (B, cyan), V128, A138, Q141 and K150 in KYK02-4 (C, cyan) and T128, A138,
L141 and K150 in KYK02-6 (D, cyan) are shown. Blue, red, white and grey cubes
represent nitrogen, oxygen, hydrogen and carbon atoms, respectively. In addition, van
derWaals surfaces of N-HR are shown in green. The side chain of the amino acid residue,
K150 (B, C and D), shows closer proximity to N-HR than L150 (A). In addition, V128 (C)
and L141 (D), which lack a hydrophilic hydroxyl group relative to T128 and Q141, are
predicted to show tighter hydrophobic interaction with corresponding residues in N-
HR, as compared to T128 (A, B and D) and Q141 (A, B and C), respectively.
162 B. Soonthornsata et al. / Virology 405 (2010) 157–164peptides by replacing non-hydrophobic residues with hydrophobic
residues to strengthen the interaction between C34 and N-HR.
Synthetic C34-derived peptides were purchased from Biologica, Co.
(Nagoya, Japan), dissolved at concentrations of 1–5 mg/ml in 50%
dimethyl sulfoxide and stored as aliquots at −85 °C. T-20 was
obtained from Roche (Basel, Switzerland) through the AIDS Research
and Reference Reagent Program (ARRRP) (Division of AIDS, NIAID,
NIH), dissolved at the concentration of 1 mg/ml in phosphate-
buffered saline, and stored as aliquots at −85 °C.
Cells
293T cells were maintained in Dulbecco's modiﬁed Eagle's
medium supplemented with 10% fetal bovine serum (10% FBS-
DMEM). TZM-bl cells were obtained from Dr. John C. Kappes, Dr.
Xiaoyun Wu and Tranzyme Inc. through the ARRRP, and were
maintained in 10% FBS-DMEM. In addition, U87.CD4.CCR5 and U87.
CD4.CXCR4 cells (Bjorndal et al., 1997) were obtained from Dr.
HongKui Deng and Dr. Dan R. Littman through the ARRRP, and were
maintained in 10% FBS-DMEM with puromycin (1 μg/ml) and G418
(300 μg/ml) (complete medium).
Viral constructs
AE-Env-recombinant proviral constructs containing the CRF01_AE
env genes, 22PL1, 29CC1, 45CC1, 98CC2 102CC2 and 107CC2, were
generated as described previously (Utachee et al., 2009). A T-20-
resistant variant of pNL4-3, pNL-T20R, was generated by introducing
two amino acid substitutions, V38E and N42S, into the pNL4-3-
derived luciferase reporter proviral DNA, pNL-envCT (Kinomoto et al.,
2005), by site-directed mutagenesis using the QuikChange® site-directed mutagenesis kit (Stratagene, Cedar Creek, TX). The expres-
sion vectors for B-Env clones, QH0692.42, TRO.11, AC10.0.29,
PREJO4541.67, pCAAN5342.A2 and SC422661.8 (Li et al., 2005; Wei
et al., 2002), and the vectors for C-Env clones, ZM249M.PL1, ZM53M.
PB12, ZM109F.PB4, ZM135M.PL10a, CAP45.2.00.G3 and CAP210.2.00.
E8 (Li et al., 2006), were obtained from Drs. Cynthia A. Derdeyn, Feng
Gao, Beatrice H. Hahn, Eric Hunter, Denise L. Kothe, Ming Li, Yingying
Li, Koleka Milsana, David C. Monteﬁori, Lynn Morris and Jesus F.
Salazar-Gonzalez through the ARRRP. Env-deﬁcient, luciferase re-
porter proviral construct, pNL-Luc-E−R+ (Tokunaga et al., 2001), was
used to generate B-Env- and C-Env-recombinant viruses. AE-Env-
recombinant viruses, pNL-T20R and pNL-Luc-E−R+, bear the ﬁreﬂy
luciferase gene in place of the viral nef gene; thus, we could monitor
the level of viral replication by measuring luciferase activity in
infected cells. In addition, the expression vectors for AE-Env, 98CC2
and pNL-T20R Env (T20R-Env), were generated by introducing SalI–
NotI fragment, which encodes Env and Rev, of Env-recombinant
proviral constructs into the mammalian expression vector, pCI-neo
(Promega, Madison, WI).
Preparation of Env-recombinant viruses
293T cells (2×105 cells/2 ml) were seeded onto a collagen-coated
6-well plate (Iwaki, Tokyo, Japan) 24 h prior to transfection. AE-Env-
recombinant viruses and pNL-T20R were prepared by transfecting
293T cells with the proviral construct (2 μg) using FuGENE HD
transfection reagent (Roche). In addition, B-Env- and C-Env-recom-
binant viruseswere prepared by transfecting 293T cells with pNL-Luc-
E−R+ (1.33 μg) and the Env-expression vector (0.67 μg). Forty-eight
hours after transfection, viral supernatants were cleared by centrifu-
gation for 5 min at 8000 rpm, and stored as aliquots at −85 °C. The
viral titer was determined by measuring the concentration of HIV-1
Gag p24 antigen in viral supernatants by enzyme-linked immunosor-
bent assay (ELISA) (Vironostika HIV-1 Antigen Microelisa System;
bioMérieux, Boxtel, The Netherlands).
Neutralization tests
The neutralization susceptibility of Env-recombinant viruses to the
peptides was examined as follows. U87.CD4.CXCR4 or U87.CD4.CCR5
cells were incubated with 2-fold serially diluted peptide (concentra-
tions varied depending on the susceptibility of the viruses, ranging
from 1 nM to 5 μM) in 100 μl complete medium for 10 min at 37 °C.
U87.CD4.CXCR4 cells were used as target cells for recombinant viruses
containing CXCR4-tropic AE-Env, 107CC2, and dual-tropic AE-Env,
29CC1 and 45CC1. In addition, U87.CD4.CCR5 cells were used as target
cells for recombinant viruses containing CCR5-tropic AE-Env, 22PL1
and 102CC2, six C-Env and six B-Env. The cells were then incubated
with viral supernatants (4 ng of p24 antigen) for 48 h. Luciferase
activity in infected cells was then measured using the Steady Glo
Luciferase assay kit (Promega) with an LB960 microplate lumin-
ometer (Berthold, BadWildbad, Germany). The inhibitory effect of the
peptide on viral replication was evaluated as a reduction in luciferase
activity in infected cells. The 50% inhibitory concentration (IC50) of
the peptide for inhibiting viral replication was calculated by the dose–
response curve using a standard function of GraphPad Prism 5
software (GraphPad Software, San Diego, CA).
Cell fusion assay
293T cells (2×105 cells/2 ml) were transfected with the HIV-1
Tat-expression vector, pRSV-Tat (1 μg), together with the expression
vector for the AE-Env, 98CC2 or T20R-Env (1 μg), in collagen-coated
6-well plates, essentially as described above. For control experiments,
Tat and Env-expression vectors were replaced with the corresponding
empty vectors, pRc/RSV (Invitrogen) and pCI-neo, respectively.
163B. Soonthornsata et al. / Virology 405 (2010) 157–164Sixteen hours after transfection, the cells were trypsinized and split
into six subcultures in a 24-well plate. Twenty-four hours later, the
transfected 293T cells were treated with the peptide (500 nM), and
then mixed with TZM-bl cells (6×104 cells). After 6-h co-culture, the
cells were lysed, and luciferase activity in the sample wasmeasured as
described above.Native-PAGE analysis for the interaction between N36 and C34-derived
peptides
TheN36peptide corresponding toN-HRof pNL4-3 (N36-wt) or pNL-
T20R (N36-T20R) (1 nmol)wasmixedwithC34orKYK02-4 (1 nmol) in
16 μl PBSon ice, and themixturewas then incubated for 30 min at 37 °C.
Some samples were then further incubated for 15 min at 50–80 °C. The
samples were mixed with 4 μl of 5× sample buffer (500 mM Tris–HCl,
pH 8.8, 50% glycerol and 0.01% bromophenol blue), and were loaded
onto 20% polyacrylamide Tris–glycine gel. Gel electrophoresis was
carried out under non-denaturing conditions in 25 mM Tris–192 mM
glycine buffer with 100 V of constant voltage for 3 h at 4 °C. The gel was
then stained with Coomassie brilliant blue G-250.Structure modeling of the interaction between newly designed peptide
and N-HR of the pNL4-3-derived T-20-resistant variant
The structure of the 6-bundle helix, consisting of N-HR and C-HR
(C34), was obtained from X-ray crystallography of N36/C34 complex
(PDB identiﬁer: 1aik) (Chan et al., 1997). All model modiﬁcations were
carried out using MOE (Molecular Operating Environment; Chemical
Computing Group Inc., ver. 2008.10), a graphics package for molecular
structure analysis.Watermoleculeswere removed fromX-ray data, and
two amino acid residues of N-HR, V38 andN42,were then replacedwith
thoseof theT-20-resistant virus, E38andS42. Complexmodels ofN-HR/
KYK02-2,N-HR/KYK02-4 andN-HR/KYK02-6were generated fromthat
of N-HR/C34, using the Mutate Prompt module. The ﬁrst and last
residues of each peptide were capped with ACE and NME, respectively,
and thenhydrogen atomsandpartial chargeswereplaced in the optimal
positions. Subsequently, ionization states and hydrogen positions were
adjusted using the Protonate 3D module. Furthermore, all models were
optimized by minimization with the AMBER9 program (Case et al.,
2005) using the FF99 force ﬁeld.Acknowledgments
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